Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Cytosorbents (CTSO) over the last 15 years, with Q2 2025 value amounting to -$1134.0.

  • Cytosorbents' Cash from Financing Activities fell 10001.15% to -$1134.0 in Q2 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 6726.14%. This contributed to the annual value of $9.3 million for FY2024, which is 3553.57% down from last year.
  • Per Cytosorbents' latest filing, its Cash from Financing Activities stood at -$1134.0 for Q2 2025, which was down 10001.15% from $6.8 million recorded in Q1 2025.
  • In the past 5 years, Cytosorbents' Cash from Financing Activities ranged from a high of $12.2 million in Q4 2023 and a low of -$571762.0 during Q1 2024
  • Over the past 5 years, Cytosorbents' median Cash from Financing Activities value was $378211.0 (recorded in 2021), while the average stood at $2.3 million.
  • Per our database at Business Quant, Cytosorbents' Cash from Financing Activities skyrocketed by 627863.8% in 2022 and then tumbled by 18355.64% in 2024.
  • Quarter analysis of 5 years shows Cytosorbents' Cash from Financing Activities stood at -$80924.0 in 2021, then skyrocketed by 6278.64% to $5.0 million in 2022, then surged by 144.21% to $12.2 million in 2023, then crashed by 98.63% to $166704.0 in 2024, then tumbled by 100.68% to -$1134.0 in 2025.
  • Its Cash from Financing Activities stands at -$1134.0 for Q2 2025, versus $6.8 million for Q1 2025 and $166704.0 for Q4 2024.